Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

Inclusion Criteria:

- Adult subjects ≥ 18 to ≤ 55 years of age

- Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm
Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm

- Body mass index (BMI) ≥18 and ≤35 kg/sq m

- Willing and able to provide written informed consent

Exclusion Criteria:

- Use of any medication (prescription, over-the-counter, herbal tea, or supplements)
within 5 days of dosing

- Use of any investigational agent or study treatment within 30 days of dosing

- Use of any protein or antibody-based therapeutic agents within 3 months of Screening

- Prior exposure to LX4211

- Use of cigarettes or any tobacco products within 2 months prior to Screening and
while participating in the study

- History of bariatric surgery or any other gastrointestinal surgery that may induce
malabsorption

- History of any major surgery within 6 months of Screening

- History of any hypersensitivity to the inactive components of LX4211

- History of renal disease or significantly abnormal kidney function tests

- History of hepatic disease or significantly abnormal liver function tests

- History of any active infection within 14 days prior to Day 1

- History of alcohol or substance abuse within 2 years prior to Day 1

- Donation or loss of >400 mL of blood or blood product within 3 months of dosing

- Positive urine glucose at Screening

- Positive urine screen for drugs of abuse, or urine test for alcohol at Screening or
Day -1

- Inability or difficulty swallowing pills

- Unable or unwilling to communicate or cooperate with the Investigator